Nipah virus (NiV) is an emerging pathogen that can cause severe respiratory illness and encephalitis in humans. The main reservoir is fruit bats, distributed across a large geographical area that includes Australia, Southeast Asia, and Africa. Incursion into humans is widely reported through exposure of infected pigs, ingestion of contaminated food, or through contact with an infected person. With no approved treatments or vaccines, NiV poses a threat to human public health and has epidemic potential. To aid with the assessment of emerging interventions being developed, an expansion of preclinical testing capability is required. Given variations in the model parameters observed in different sites during establishment, optimisation of challenge routes and doses is required. Upon evaluating the hamster model, an intranasal route of challenge was compared with intraperitoneal delivery, demonstrating a more rapid dissemination to wider tissues in the latter. A dose effect was observed between those causing respiratory illness and those resulting in neurological disease. The data demonstrate the successful establishment of the hamster model of NiV disease for subsequent use in the evaluation of vaccines and antivirals.
19 January 2026 in Frontiers in Veterinary Science
Nipah virus (NiV) is recognised as a priority pathogen with pandemic potential by the World Health Organisation (WHO). The NiV-Bangladesh strain (NiV-B) has been associated with recent outbreaks in different districts of Bangladesh and the state of Kerala (India), and it is suggested to be more pathogenic and lethal than the NiV-Malaysian strain (NiV-M). In this study, we aimed to describe the clinical signs and pathology of NiV-B using the golden Syrian hamster model following intranasal (IN) and intraperitoneal (IP) inoculation with different doses and to compare with prior NiV-M results. For this purpose, we selected samples from NiV-B-infected animals that were submitted for H&E evaluation, immunohistochemistry (IHC), in situ hybridisation (ISH) (RNAscope technique), and multiplex immunofluorescence (mIF). The absence of neurological signs was observed in NiV-B-infected animals compared with those that were NiV-M-infected. Except for the brain, which did show only mild lesions, histopathological analysis of NiV-B demonstrated similar pathology and viral RNA in the lung, spleen, and liver compared to those of NiV-M infected animals, with the lung being the main affected organ. Pulmonary lesions consisted of areas of broncho-interstitial pneumonia associated with high cell death activation (caspase-3), proliferation (Ki67), and abundant intralesional macrophages (Iba1) and T cells (CD3). Differential upregulation of the cytokine IL-6 was observed in the lung from NiV-B compared with NiV-M infected animals. Moreover, we demonstrated the wide distribution of the NiV receptor ephrin B2 in endothelial cells, neurons, smooth muscle, epithelial cells, macrophages/type II pneumocytes, and T cells.
Nipah virus (NiV) is a highly pathogenic zoonotic virus for which no licensed vaccines or therapeutics are currently available, necessitating well-characterised animal models to support countermeasure development. This study aimed to establish an appropriate challenge dose in the Syrian golden hamster model at the UK Health Security Agency (UKHSA), incorporating both intraperitoneal (i.p.) and intranasal (i.n.) routes of infection and two clinically relevant strains, NiV-Malaysia (NiV-M) and NiV-Bangladesh (NiV-B). Due to a different challenge doses and susceptibilities of hamsters to NiV being reported in the literature, there is a prerequisite to define the model parameters upon establishment in a new facility. Dose-ranging studies were performed across multiple independent experiments assessing survival, clinical progression and histopathological outcomes. Challenge via the i.p. route produced consistent and severe disease using an infectious dose of 103 TCID50 for both strains. In contrast, animals were more susceptible to infection via i.n. challenge with a dose of 10 TCID50 resulting in uniform lethality. For both challenge routes, respiratory and neurological disease manifestations were observed. These distinct disease phenotypes were supported by histopathological findings and viral RNA distribution in affected organs. Differences between strains were evident, with NiV-B showing a tendency towards a broader pulmonary pathology at lower doses after i.n. challenge. Collectively, these findings demonstrate that challenge dose, route of exposure, and viral strain influence disease outcomes in the hamster model.